Impel NeuroPharma Completes Industry's First Nose-to-Brain Human Imaging Study

SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma announced today the completion of its human proof of concept study with the POD technology demonstrating nose-to-brain delivery using SPECT imaging, a first in the pharmaceutical and biotechnology industries. The successful trial opens the door for central nervous system (CNS) drugs to be delivered directly to the human brain, allowing potential treatments for complex neurological conditions that were previously excluded by the blood-brain barrier (BBB). Imaging showed that the POD device successfully deposited a therapeutic amount of radiolabeled tripeptide into the deep nasal cavity that then enabled rapid and significant delivery to the central nervous system, bypassing the BBB.